NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more
NextCure Inc (NXTC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.265x
Based on the latest financial reports, NextCure Inc (NXTC) has a cash flow conversion efficiency ratio of -0.265x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.27 Million) by net assets ($23.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NextCure Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NextCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NextCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NextCure Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Laboratorios Richmond SACIF
BA:RICH
|
0.003x |
|
NEORIGIN Co. Ltd
KQ:094860
|
-0.069x |
|
H-FARM SPA
F:5JQ
|
N/A |
|
Maniker
KO:027740
|
0.165x |
|
Kora Saude Participacoes SA
SA:KRSA3
|
0.020x |
|
Edisun Power Europe AG
SW:ESUN
|
0.008x |
|
Dorel Industries Inc
PINK:DIIBF
|
0.634x |
|
POZNANSKA K.BUD.P. A ZY1
F:20W
|
N/A |
Annual Cash Flow Conversion Efficiency for NextCure Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of NextCure Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $65.47 Million | $-40.80 Million | -0.623x | -34.62% |
| 2023-12-31 | $114.42 Million | $-52.97 Million | -0.463x | -43.94% |
| 2022-12-31 | $167.53 Million | $-53.89 Million | -0.322x | -31.14% |
| 2021-12-31 | $233.39 Million | $-57.24 Million | -0.245x | -60.26% |
| 2020-12-31 | $293.72 Million | $-44.95 Million | -0.153x | -38.12% |
| 2019-12-31 | $321.48 Million | $-35.62 Million | -0.111x | +34.91% |
| 2018-12-31 | $-46.94 Million | $7.99 Million | -0.170x | -133.21% |
| 2017-12-31 | $-24.41 Million | $-12.51 Million | 0.513x | -- |